Showing results (181-190 of 199) with videos related to
Sort By:
Pageof 20
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2002
The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutionsA F Ferreira Filho, A Di Leo, M Paesmans, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2011
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapyA Hendlisz, V Golfinopoulos, C Garcia, et al.British Journal of Cancer|March 23, 2013
Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patientsP El Hajj, F Journe, M Wiedig, et al.Cancer Chemotherapy and Pharmacology|April 2, 1998
A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I studyO van Tellingen, C J Punt, A Awada, et al.European Journal of Cancer (Oxford, England : 1990)|November 21, 2002
Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumoursA Awada, F A L M Eskens, M Piccart, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumorsF A Eskens, A Awada, D L Cutler, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2004
Phase II study of E7070 in patients with metastatic melanomaJ F Smyth, S Aamdal, A Awada, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2002
Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedulesA Awada, S Giacchetti, B Gerard, et al.British Journal of Cancer|June 13, 2015
SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanomaP El Hajj, D Gilot, M Migault, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 4, 2014
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancerF Rothé, J-F Laes, D Lambrechts, et al.Pageof 20